Table 1 KEGG and GO enrichment analysis
From: miRNAs and sports: tracking training status and potentially confounding diagnoses
Category | Database | Target genes on category | Expectation value | Enrichment | p value |
|---|---|---|---|---|---|
Melanoma | KEGG | 17 | 3.7 | 4.6 | 3.10E−06 |
Bladder cancer | KEGG | 13 | 2.4 | 5.4 | 1.36E−05 |
Cell cycle | KEGG | 19 | 5.3 | 3.6 | 1.83E−05 |
Glioma | KEGG | 15 | 3.4 | 4.4 | 1.83E−05 |
G1_phase(4) & mitotic_G1_phase(5) | GO | 11 | 1.3 | 8.3 | 2.34E−05 |
Viral carcinogenesis | KEGG | 20 | 6.0 | 3.3 | 2.59E−05 |
Pancreatic cancer | KEGG | 16 | 4.1 | 4.0 | 2.72E−05 |
Chronic myeloid leukemia | KEGG | 17 | 4.6 | 3.7 | 3.04E−05 |
Non-small cell lung cancer | KEGG | 12 | 3.1 | 3.9 | 5.86E−04 |
p53 signaling pathway | KEGG | 11 | 3.2 | 3.4 | 3.44E−03 |
Thyroid cancer | KEGG | 6 | 1.4 | 4.3 | 2.67E−02 |
Biological_phase(2) | GO | 15 | 4.9 | 3.1 | 4.68E−02 |
Cell_cycle_phase(3)&mitotic_cell_cycle_phase(4) | GO | 15 | 4.6 | 3.3 | 4.68E−02 |
Cell_maturation(5) | GO | 14 | 4.2 | 3.3 | 4.68E−02 |
Regulation_of_fibroblast_proliferation(5) | GO | 12 | 3.3 | 3.6 | 4.68E−02 |
Positive_regulation_of_fibroblast_proliferation(5) | GO | 10 | 2.3 | 4.3 | 4.68E−02 |
Interphase(4) | GO | 9 | 1.9 | 4.8 | 4.68E−02 |
Hair_follicle_morphogenesis(4) | GO | 7 | 1.2 | 6.0 | 4.68E−02 |